Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KDM6B | O15054 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Isonicotinate SCHEMBL820082 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| Methyl Isonicotinate SCHEMBL9213497 | 0.98 | LMNA (0.58) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| Methyl Isonicotinate SCHEMBL29827431 | 0.98 | LMNA (0.58) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| Methyl Isonicotinate SCHEMBL9217491 | 0.98 | LMNA (0.58) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| Methyl Isonicotinate SCHEMBL28185382 | 0.88 | LMNA (0.50) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| SCHEMBL741537 | 0.87 | HDAC1 (0.58) | TSHRALDH1A1CA1CA2TDP1 | |
| SCHEMBL13019478 | 0.87 | HDAC1 (0.58) | TSHRALDH1A1CA1CA2TDP1 | |
| Methyl Isonicotinate SCHEMBL28162148 | 0.87 | TSHR (0.52) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| Methyl Isonicotinate SCHEMBL28213363 | 0.85 | ALDH1A1 (0.50) | CYP1A2CYP2C19TSHRLMNACYP2C9 | |
| SCHEMBL23999861 | 0.84 | KMT2A (0.57) | TSHRSMN1; SMN2ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1923 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648744-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | Pheromones Biotech LLP (IN) | 2025-11-19 | — | — | EP | claimed |
| US-20250161201-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2025-05-22 | — | — | US | claimed |
| CN-119330960-A | Novel selenium-rhodamine photosensitizer and synthesis method thereof | 山西大学 | 2025-01-21 | — | — | CN | claimed |
| EP-4479146-A1 | COSMETIC COMPOSITION | The Boots Company PLC (GB) | 2024-12-25 | — | — | EP | claimed |
| CN-115010900-B | Azobenzene liquid crystal elastomer with photo-thermal double response and reversible deformation and preparation method thereof | 广东石油化工学院 | 2024-10-15 | — | — | CN | claimed |
| CN-118745147-A | Cobalt-catalyzed method for preparing isonicotinic acid compound by taking carbon dioxide as carboxyl source | 南开大学 | 2024-10-08 | — | — | CN | claimed |
| WO-2024150040-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | PHEROMONES BIOTECH LLP (IN) | 2024-07-18 | — | — | WO | claimed |
| US-20240237642-A1 | CONTROLLED RELEASE SEMI-SOLID EMULSION FORMULATIONS OF SEMIOCHEMICALS | PHEROMONES BIOTECH LLP (IN) | 2024-07-18 | — | — | US | claimed |
| CN-118005944-A | Antibacterial metal organic framework composite material and preparation method and application thereof | 中国科学院赣江创新研究院 | 2024-05-10 | — | — | CN | claimed |
| CN-114773262-B | Synthesis method of 2-cyano-4-pyridine carboxylic acid methyl ester | 兄弟科技股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998022468-A1 | PSORALEN SENSITIZERS FOR VIRAL INACTIVATION | OHIO STATE RESEARCH FOUNDATION (US) | 1998-05-28 | — | — | WO | claimed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | claimed |
| US-4761467-A | REACTING METHANOL, CARBON MONOXIDE AND OXYGEN TO PRODUCE DIMETHYL CARBONATE WITH A CUPRIC METHOXYCHLORIDE-PYRIDINE COMPOUND CATALYST | TEXACO INC. (US) | 1988-08-02 | — | — | US | claimed |
| US-4625021-A | High yield process for preparing beta-lactam antibiotics having a high purity degree | ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A. (IT) | 1986-11-25 | — | — | US | claimed |
| EP-0095341-B1 | PENICILLANIC ACID DIOXIDE PRODRUG | PFIZER INC. (US) | 1986-02-26 | — | — | EP | claimed |
| EP-0095341-A1 | Penicillanic acid dioxide prodrug | PFIZER INC. (US) | 1983-11-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161201-A1 | COSMETIC COMPOSITION | CYP19A1, SHBG, HSD17B11 | CYP1A2 354/4885CYP2C19 110/4885TSHR 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.